Crispr (CRSP) Stock Price Today & Analysis
CRSP
Valuation
Market cap$5.13B
Price-to-sales ratio133.84
Price-to-book value2.68
Price-earnings ratio-10.50
Return on Equity-26.00%
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-5.57
Income Statement
Average volume1,638,449
EBITDA$-465.92M
1 year high (52w)$78.48
1 year low (52w)$30.04
Dividend
Dividend yield0.00%
Solvency
Debt-to-equity ratioN/A
About Crispr
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
FAQ
You can easily purchase Crispr (CRSP) shares through the Gotrade app. Simply download the app, set up your account, fund it, and then search for the 'CRSP' ticker to begin your investment journey.
At Gotrade, you can kickstart your investment in Crispr with as little as $1.
Absolutely. Brokerage services on Gotrade Indonesia are provided by PT Valbury Asia Futures, a licensed futures and commodities broker registered with and supervised by the Indonesian Financial Services Authority (OJK).
Yes. Gotrade provides access to U.S. stocks from Indonesia through fully backed shares. This is facilitated through a cross-border order routing scheme for foreign stock derivative contracts (PALN), in accordance with regulations from Bappebti (the Commodity Futures Trading Regulatory Agency).
When you trade, you enter into a contract with PT Valbury Asia Futures (Valbury), a Bappebti-registered broker in Indonesia. Valbury, in turn, fully backs its contracts 1-for-1 with Alpaca Securities LLC, a FINRA-licensed broker-dealer in the United States. For every share (or fraction thereof) you hold on Gotrade, a corresponding share is held by Valbury in a separate, segregated brokerage account at Alpaca Securities LLC.
